Results 21 to 30 of about 10,858 (213)

Tenofovir-Containing Antiretroviral Therapy and Clinical Outcomes of SARS-CoV-2 Infection in People Living with HIV

Viruses, 2023
Tenofovir has been hypothesized to be effective against COVID-19 and is available as two prodrugs, tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF), both part of antiretroviral therapy (ART) regimens.
María F. Rombini, Diego Cecchini, Sofía Diana Menendez, Liliana Calanni, Rosana Cuini, Elena Obieta, María M. Greco, Fabricio Morales, Laura Morganti, Claudia Migazzi, Yasmin El Kozah, Pablo Parenti, Isabel Cassetti, on behalf of the COVIDARE Study Team   +13 more
doaj   +1 more source

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study [PDF]

, 2016
BACKGROUND: Tenofovir alafenamide (TAF) is a novel tenofovir prodrug with improved renal and bone safety compared with TDF-containing regimens. We report the 48 week safety and efficacy of a once-daily single tablet regimen of elvitegravir 150 mg (E ...
Abram, Michael E., Arribas, Jose R., Avihingsanon, Anchalee, Benson, Paul, Bloch, Mark, Cheng, Andrew, Chetchotisakd, Ploenchan, Crofoot, Gordon, Custodio, Joseph M., Fordyce, Marshall W., Gathe, Joseph, Gupta, Samir K., Lichtenstein, Kenneth, McCallister, Scott, Post, Frank A., Pozniak, Anton, Ramgopal, Moti, SenGupta, Devi, Wei, Xuelian   +18 more
core   +1 more source

RP-HPLC method development and validation for the estimation of Emtricitabine, Bictegravir and Tenofovir alafenamide in bulk and pharmaceutical dosage form

Journal of Taibah University for Science, 2019
A new simple, accurate, precise RP-HPLC [reverse phase high performance liquid chromatography] method was developed for the simultaneous estimation of the Emtricitabine, Bictegravir and Tenofovir alafenamide in pharmaceutical dosage form.
Tej Kumar Kokkirala, Duvvuri Suryakala
doaj   +1 more source

Association of Tenofovir Use With Risk of Incident Heart Failure in HIV-Infected Patients. [PDF]

, 2017
BackgroundThe antiretroviral medication, tenofovir disoproxil fumarate (TDF), is used by most human immunodeficiency virus-infected persons in the United States despite higher risks of chronic kidney disease.
Chen, Ruijun, Estrella, Michelle M, Grunfeld, Carl, Horberg, Michael A, Hsue, Priscilla Y, Jotwani, Vasantha, Scherzer, Rebecca, Shlipak, Michael G   +7 more
core   +1 more source

Week 48 resistance analyses of the once-daily, single-tablet regimen darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials [PDF]

, 2019
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is being investigated in two Phase III trials, AMBER (NCT02431247; treatment-naive adults) and EMERALD (NCT02269917; treatment-experienced, virologically suppressed ...
Ajana, F, Antela, A, Antinori, A, Arasteh, K, Arribas, JR, Baugh, Bryan, Belonosova, E, Benson, P, Berenguer, J, Bhatti, L, Bickel, M, Bogner, J, Bredeek, F, Brown, Kimberley, Brunetta, J, Casado, J, Castelli, F, Chernova, O, Chirianni, A, Clarke, A, Conway, B, Cotte, L, Crofoot, G, Cunningham, D, De Los Santos, I, De Luca, A, De Meyer, Sandra, De Wit, S, DeJesus, E, deVente, J, Di Biagio, A, Dushkina, N, Eron, J, Esser, S, Estrada, V, Faetkenheuer, G, Felizarta, F, Florence, E, Franco, R, Galindo, MJ, Gallant, J, Galli, M, Garcia Del Toro, M, Garlicki, A, Gasiorowski, J, Gatell, JM, Gazzard, BG, Ghys, Anne, Girard, P-M, Gorgolas, M, Gutierrez, F, Gutierrez, MDM, Hagins, D, Halota, W, Henry, K, Horban, A, Jayaweera, D, Jessen, H, Jezorwski, John, Johnson, MA, Katlama, C, Kern, W, Klein, M, Kulagin, V, Lathouwers, Erkki, Lazzarin, A, Lucasti, C, Maggiolo, F, Martorell, C, Maserati, R, McDonald, C, McGowan, J, Mills, A, Mohsine, El Ghazi, Molina, J-M, Morales-Ramirez, J, Moutschen, M, Murphy, D, Mussini, C, Negredo, E, Opsomer, Magda, Orkin, C, Parczewski, M, Piekarska, A, Pineda, JA, Podzamczer, D, Poizot-Martin, I, Portilla Sogorb, J, Prelutsky, D, Rachlis, A, Raffi, F, Ramgopal, M, Rashbaum, B, Reeves, I, Rey, D, Reynes, J, Rivero, A, Rockstroh, J, Ruane, P, Rubio, R, Ryamova, E, Shafran, S, Shuldyakov, A, Sizova, N, Slim, J, Spinner, C, Stellbrink, H-J, Stoehr, A, Teicher, E, Tsybakova, O, Van Landuyt, Erika, Van Wijngaerden, E, Vandekerckhove, L, Vandercam, B, Vekerckhove, L, Vercam, B, Viciana, P, Voronin, E, Walmsley, S, Waters, L, Wilkin, A, Wong, Eric Y, Yakovlev, A, Yazdanpanah, Y   +123 more
core   +3 more sources

A pharmacist-led medication switch protocol in an academic HIV clinic: patient knowledge and satisfaction

BMC Infectious Diseases, 2018
Background Tenofovir alafenamide (TAF) is associated with less renal and bone toxicity compared with tenofovir disoproxil (TDF). TAF's recent FDA approval has spurred HIV providers to consider switching antiretroviral therapy (ART) regimens containing ...
Sarah S. Lee, Joshua P. Havens, Harlan R. Sayles, Jennifer L. O’Neill, Anthony T. Podany, Susan Swindells, Kimberly K. Scarsi, Sara H. Bares   +7 more
doaj   +1 more source

Week 96 Results of Switching from Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide among HIV/Hepatitis B Virus-Coinfected Patients

Microbiology Spectrum, 2023
Data regarding the durability of tenofovir alafenamide (TAF)-containing antiretroviral therapy (ART) in maintaining hepatitis B virus (HBV) viral suppression among HIV/HBV-coinfected patients are limited.
Yu-Shan Huang, Chien-Yu Cheng, Hsin-Yun Sun, Shu-Hsing Cheng, Po-Liang Lu, Chen-Hsiang Lee, Yuan-Ti Lee, Hung-Chin Tsai, Chia-Jui Yang, Chun-Eng Liu, Bo-Huang Liou, Shih-Ping Lin, Sung-Hsi Huang, Mao-Wang Ho, Hung-Jen Tang, Chien-Ching Hung   +15 more
doaj   +1 more source

Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort [PDF]

, 2019
Introduction: Concerns about dolutegravir (DTG) tolerability in the real-life setting have recently arisen. We aimed to estimate the risk of treatment discontinuation and virological failure of DTG-based regimens from a large cohort of HIV-infected ...
Abeli C., Acinapura R., alungo A., Andreoni M., Angarano G., Antinori A., aracino A., atini A., azzarin A., Bagella P., Bai F., Baldelli F., Baldin G., Balotta C., Bandera A., Barocci V., Bassetti M., Blanc P., Bobbio N., Bonfanti P., Bonora S., Borderi M., Borgia G., Cacopardo B., Calcagno A., Capetti A., Capobianchi M. R., Capozzi M., Caramello P., Carletti F., Carrara S., Cascio A., Cassola G., Castagna A., Castelli F., Castelnuovo F., Cattelan A. M., Cauda R., Ceccherini-Silberstein F., Ceccherini-Silberstein F., Cecchetto M., Celesia B., Chiodera A., Cicalini S., Cingolani A., Cinque P., Colomba C., Costantini A., Cozzi-Lepri A., Cozzi-Lepri A., Cristaudo A., d'Arminio Monforte A., De Luca A., Di Biagio A., Di Caro A., Di Giuli C., Di Martino F., Di Perri G., Esposito V., Fabrizio C., Falasca K., Fanti I., Fontana Del Vecchio R., Francisci D., Galli L., Galli M., Gentile I., Giacometti I. A., Gianotti N., Girardi E., Gori A., Graziano S., Guaraldi G., i V., Iaiani G., Iardino R., Ippolito G., Lapadula G., lessandrini A., Lichtner M., Lo Caputo S., Lorenzini P., Lorenzotti S., Macchia M., Maddaloni L., Madeddu G., Maggiolo F., Maggiolo F., Magnani G., Manfrin V., Marchetti G., Marinello S., Mastrorosa I., Mazzarello G., Menzaghi B., Migliorino C., Milini P., Minardi C., Moioli M. C., Molteni C., Mondi A., Monno L., Mussini C., Nozza S., Nunnari G., ondero A., Orofino G. C., Pan A., Parruti G., Pellicano G., Pellizzer G., Perno C. F., Petrone F., Piolini R., Plazzi M. M., Pozzetto I., Prota G., Puoti M., Puzzolante C., Quartu S., Quiros Roldan E., Rezza G., Ridolfo A. L., Rivano Capparucia M., Rizzardini G., Rodano' A., Rossetti B., Rossotti R., Rusconi S., Rusconi S., Salpietro S., Sangiovanni V., Santoro M. M., Sarmati L., Savinelli S., Schiaroli E., Sciandra M., Segala D., Sighinolfi L., Sozio F., Starnini G., Suardi C., Tavelli A., Tavelli A., Tincati C., Truffa S., Ursitti M. A., Vecchiet J., Vergori A., Verucchi G., Viale P., Vichi F., Viscoli C., Viviani F., von Schloesser F., Vullo V.   +155 more
core   +4 more sources

The role of drug transporters in the kidney: lessons from tenofovir [PDF]

, 2014
Tenofovir disoproxil fumarate, the prodrug of nucleotide reverse transcriptase inhibitor tenofovir, shows high efficacy and relatively low toxicity in HIV patients.
Moss, DM, Neary, M, Owen, A
core   +2 more sources

Tenofovir Alafenamide Rescues Renal Tubules in Patients with Chronic Hepatitis B

Life, 2021
Nucles(t)ide analogs (NAs) are effective for chronic hepatitis B (CHB). NAs suppress hepatic decompensation and hepatocarcinogenesis, leading to a dramatic improvement of the natural course of patients with CHB.
Tomoya Sano, Takumi Kawaguchi, Tatsuya Ide, Keisuke Amano, Reiichiro Kuwahara, Teruko Arinaga-Hino, Takuji Torimura   +6 more
doaj   +1 more source